Floatz logo

Atezolizumab

Her2-Receptor Negative Breast Cancer

TransThera Sciences (Nanjing), Inc.monoclonal_antibodyPhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

185 Active assets in the Her2-Receptor Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
Exemestane
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Docetaxel
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2/3BB
Durvalumab
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmActive
BB
Indicative · Phase 2/3
71 / 100
View asset →
bladder transitional cell carcinomaActive
BB
Indicative · Phase 3
68 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 3
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →